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1. INTRODUCTION 
 
AIDS is a life threatening disease caused by HIV (human immunodeficiency virus).HIV 
makes it difficult for the body to fight off infections. The high prevalence and mortality of 
HIV/AIDS led to a revolution in the care of patients with HIV/AIDS1. 
 
 PREVALENCE OF AIDS 2 
 
 HIV disease continues to be a serious health issue for parts of the world. 
 
 About 34.2 million people are living with HIV around the world. In 2010, there were 
about 1.8 million deaths in persons with AIDS, and nearly 30 million people with 
AIDS have died worldwide since the epidemic began. 
 
 In 2012, there were 35.3 million [32.2 million–38.8 million] people living with HIV. 
1.6 million [1.4 million–1.9 million] people died from AIDS-related cause 
worldwide.       
 
 India has 2.4 million HIV positive people. It’s estimated that out of these 61% are 
male, 39% are female and 3.5% are children. 
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                                       TABLE 1: Prevalence of HIV-AIDS in the world 
 
 
 
 
 
 
 
 
 
 2005 2006 2007 2008 2009 2010 2011 2012 
 
(in millions) 
 
People living with  
HIV 
32.5 32.8 33.2 33.5 34 34.4 34.9 35.3 
New HIV 
infections (total) 
2.9 2.8 2.7 2.6 2.6 2.5 2.5 2.3 
New HIV 
infections (adults) 
2.3 2.3 2.2 2.2 2.2 2.2 2.2 2.0 
New HIV 
infections 
(children) 
540000 520000 480000 450000 400000 360000 310000 260000 
AIDS related 
deaths 
2.3 2.3 2.2 2.1 2.0 1.9 1.8 1.6 
People  accessing 
treatment 
1.3 2.0 2.9 4.1 5.3 6.6 8.1 9.7 
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COMPLICATIONS OF AIDS 
 
 
 
     
                                              Fig 1: Complications of HIV 
TREATMENT 3-5 
The reason HIV has become a more manageable disease instead of a death knell is 
because of something called anti-retroviral therapy in which a cocktail of drugs are given to HIV 
positive people which helps them manage their condition and prevents HIV from becoming 
AIDS. 
NRTIs form the backbone of antiretroviral (ARV) cocktail and zidovudine (ZDV) and 
stavudine (d4T) are the most preferred NRTIs widely used in the first line management for HIV 
treatment. 
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Nucleoside reverse transcriptase inhibitors (NRTIs) in combinations with other 
antiretrovirals (HAART) are the cornerstones of acquired immunodeficiency syndrome (AIDS) 
therapy, turning HIV infection into a manageable chronic illness. 
AZT which is the thymidine analogue (a potent inhibitor of the replication of human 
immunodeficiency virus) is the first U.S. government-approved treatment for HIV therapy, 
prescribed under the name Retrovir. AZT was the first breakthrough in AIDS therapy, 
significantly reducing the replication of the virus in patients and leading to clinical and 
immunologic improvements.  
 
MECHANISM BY WHICH ZIDOVUDINE WORKS? 6 
 
AZT works by selectively inhibiting HIV's reverse transcriptase, the enzyme that the 
virus uses to make a DNA copy of its RNA. Reverse transcription is necessary for production of 
HIV's double-stranded DNA, which would be subsequently integrated into the genetic material 
of the infected cell (where it is called a provirus). 
 
WHY ZIDOVUDINE IS GIVEN IN COMBINATION? 7, 8 
 
AZT is not potent enough to prevent all HIV replication, and may only slow the 
replication of the virus and the progression of the disease. During prolonged AZT treatment, HIV 
has the potential to develop resistance to AZT by mutation of its reverse transcriptase. To slow 
the development of resistance, physicians generally recommend that AZT be given in 
combination with another reverse transcriptase inhibitor and an antiretroviral from another 
group, such as a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor; this type 
of therapy is known as HAART (Highly Active Anti Retroviral Therapy). 
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Azidothymidine (AZT) was first administered to patients in 1985. It remains the primary 
drug and the only antiviral agent approved for initial treatment of human immunodeficiency 
virus (HIV) positive patients. However, serious side effects have occurred in clinical studies with 
AZT, resulting in dose reduction or discontinuation of the drug completely. 
 
 
ANEMIA AND AIDS  9-11 
 
                                                  
                                                               Fig 2: Anemia 
                                            
 One of the side effects is anemia. Anemia is a frequent complication of infection with the 
human immunodeficiency virus type 1 (HIV-1) and may have multiple causes.                                   
    
  Anemia has been associated with progression to AIDS and shorter survival times for HIV-
infected patients 
 
HIV infection and its direct effects on HSCs and stromal elements can lead to anemia. 
Opportunistic infection and myelosuppressive drugs might also cause anemia. 
The anemia associated with zidovudine treatment is macrocytic, and indeed the red cells may be 
macrocytic even without anemia. Finally, anemia can be a result of red cell destruction, or 
hemolysis, as opposed to an aberration of production. 
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The etiology of anemia in HIV infection is multifactorial and typically the anemia may 
result from low production of red blood cells, increased RBC destruction, or ineffective RBC 
production. Other mechanisms for HIV-associated anemia, although uncommon, include vitamin 
B12 deficiency and the autoimmune destruction of erythrocytes. Direct infection of marrow 
precursor cells. Red blood cells develop from immature cells in the bone marrow called 
erythroid progenitor cells. When the number or maturation of these progenitor cells is impaired, 
anemia can result. 
 
PATHOPHYSIOLOGY OFANEMIA IN HIV INFECTED PERSONS 12 
 
 An obvious cause of anemia in patients with HIV infections blood loss. Pathophysiology 
of HIV-associated anemia may involve 3 basic mechanisms. 
 
(a) Decreased RBC production 
 
(b) Increased RBC destruction 
 
(c) Ineffective RBC production 
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                   Table 2: Pathophysiology of anemia in HIV infected persons  
 
 
DECREASED RBC 
PRODUCTION
• Infiltration of bone 
marrow by infection-
• Use of 
myelosuppressivedrug
• HIV infection itself
• Decreased production of 
erythropoietin
• Blunted response to 
erythropoietin
INCREASED RBC 
DESTRUCTION
• RBC autoantibodies, 
hemophagocytic 
syndrome
• Disseminated 
intravascular coagulation
• Thrombotic 
thrombocytopenic 
purpura
• Glucose 6-phophate 
dehdrogenase deficiency
INEFFECTIVE RBC 
PRODUCTION
• Folic acid deficiency 
caused  by either dietary 
deficieny or jejunal 
deficiency
• Vitamin B12 deficiency 
caused by malabsorption 
in the ileum 
• Pathology caused by 
array of infections
• Conditions that affect the 
gastric mucosa in HIV-
infected patients
INTRODUCTION 
 
Dept.of Pharmacy Practice, JKKN, Kumarapalayam Page 8 
 
 
 
 
SYMPTOMS OF ANEMIA 
                             
              
     
 
 
                                                           Fig 3: Symptoms of anemia 
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TUBERCULOSIS ASSOCIATED WITH AIDS 13 
 
Tuberculosis is the most common human immunodeficiency (HIV) virus-related 
opportunistic infection in India and caring for patients with both diseases is a major public health 
challenge. It is estimated that 60-70% of HIV-positive persons will develop tuberculosis in their 
lifetime. Approximately, 50% of adult Indian population is infected with Mycobacterium 
tuberculosis, and the spread of HIV infection could lead to a potentially explosive increase in the 
number of cases of tuberculosis. About 1.8 million new cases of tuberculosis are occurring 
annually in India. HIV infection is the most important known risk factor that favors progression 
to active TB from latent infection by suppressing the immune response against tuberculosis.  
There are two types of tuberculosis infection, latent and active. 
                                                    Table 3: Types of tuberculosis 
Active TB Latent TB 
In case of active TB, due to the 
weak immune system, the germs 
multiply and cause symptoms. 
In case of latent TB, the germs 
remain in the body and do not 
cause symptoms. 
 
Active disease is more likely associated with HIV; especially if CD4 count is less 
than 200.Active tuberculosis can happen no matter what the CD4 level is. If infected with 
both HIV and TB, atleast 10 times the person is more likely to develop active TB than 
someone without HIV.  
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COMMON COMPLAINTS OF TB ASSOCIATED WITH AIDS 
 A cough that lasts for more than two to three weeks 
 Coughing up phlegm or blood 
 Chest pain 
 Weakness or fatigue 
 Weight loss 
 Lack of appetite 
 Fever or chills 
 Night sweats 
A CO-EPIDEMIC 14-16 
HIV and tuberculosis (TB) are so closely connected that their relationship is often described as 
a co-epidemic. The two diseases are a deadly combination; they are far more destructive together 
than either disease alone. In developing countries many people infected with HIV contract TB as 
the first sign of AIDS. At least one-third of the 38.6 million HIV-positive people in the world is 
also infected with TB and is at greatly increased risk of developing TB disease (the active and 
contagious form of TB). 
Tuberculosis (TB) and HIV have been closely linked since the emergence of AIDS. 
Worldwide, TB is the most common opportunistic infection affecting HIV-seropositive 
individuals, and it remains the most common cause of death in patients with AIDS. 
By producing a progressive decline in cell-mediated immunity, HIV alters the pathogenesis of 
TB, greatly increasing the risk of disease from TB in HIV-coinfected individuals and leading to 
more frequent extra pulmonary involvement, atypical radiographic manifestations, and 
paucibacillary disease, which can impede timely diagnosis. Although HIV-related TB is both 
treatable and preventable, incidence continues to climb in developing nations. 
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SYMPTOMS OF TUBERCULOSIS IN AIDS PATIENTS 
 
 
 
                             Fig 4: Symptoms of Tuberculosis in AIDS patients 
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2. REVIEW OF LITERATURE  
 
1. Mohsen Meidani et al. (2012)17 studied Prevalence, severity, and related factors of 
anemia in HIV/AIDS patients and have reported that anemia is slightly more common in women 
than men.         
 
2.   Akinsegun Akinbami et al. (2010)18 evaluated Hematologic Abnormalities in 
Treatment-Naïve HIV Patients and have concluded that about one-fifth of HIV treatment-naïve 
patients were cytopenic at enrollment and the degree of cytopenia was directly related to the 
degree of immunosupression. It is necessary to investigate various causes of cytopenia in these 
patients so as to administer a specific intervention. 
 
3. Anuja Balakrishnan et al. (2010)19 reported Zidovudine- induced reversible pure red 
cell aplasia and have studied the first case of Zidovudine induced PRCA reported from the 
Indian subcontinent. 
 
4. José A Mata-Marín et al. (2010)20 studied factors and correlates for anemia in HIV 
treatment-naïve infected patients and have concluded that Anemia is a common manifestation in 
the Mexican population without antiretroviral therapy. In HIV naïve patients, a CD4+ Cell Count 
<200 cells/mm3 was associated with an increased risk of anemia. There is a positive correlation 
between hemoglobin and CD4+ cell count. 
 
5. Dipti Agarwal et al. (2010)21 studied high incidence of zidovudine induced anemia in 
HIV infected patients in eastern India and have concluded that out of 16.2% patients, 7.9% 
patients developed severe anemia and that females were more prone to develop anaemia. 
 
6. Sara jam MD et al. (2009)22 reported A Cross-Sectional Study of Anemia in Human 
Immunodeficiency Virus-Infected Patients in Iran and have stated that AZT-based highly active 
antiretroviral therapy (HAART) had a greater negative impact on hematologic parameters 
compared with the d4Tbased regimens. 
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7.  Melanie-anne A et al. (2008)23 reported Lamivudine-induced red cell aplasia and have 
indicated that the onset appears to be variable and occurs at any CD4+ count, but rapid 
improvement after cessation of drug administration appears to be a consistent feature. 
 
8. Yulistiani et al. (2007)24 reported the ‘drug utilization profile in HIV/aids patients and 
have concluded that the drug profile used in HIV/AIDS patients are the first line 
ARV consisted of NRTIs (3TC, AZT) and NNRTIs (NVP, EFV); antimicrobial treatment 
including antibiotics and antifungal agents; and others to prevent or to treat opportunistic 
infections. ADRs occurred in 21% patients receiving ARV therapy.  
 
9.Rochelle Chodock et al.(1999)25 reported Survival of a human immunodeficiency 
patient with nucleoside-induced lactic acidosis-role of haemodialysis treatment and have 
concluded that life threatening lactic acidosis is an unusual but significant complication of 
antiretroviral treatment with nucleoside analogues and that discontinuation of the nucleoside 
analogue, intensive supportive care and high dose intravenous bicarbonate may not be sufficient 
therapy.Hemodialysis may confer benefits and improve survival. 
 
 
10. Patrick S Sullivanet al. (1998)26 studied the Epidemiology of Anemia in Human 
Immunodeficiency Virus (HIV) - Persons: Results From the Multistate Adult and Adolescent 
Spectrum of Infected HIV Disease Surveillance Project and have indicated that Anemia in HIV-
infected patients, if persistent, is associated with substantially decreased survival and 
consideration should be given to evaluating the effects of treating anemia in a prospective study 
design. If recovery from anemia is shown to directly increase survival, screening for anemia 
should be aggressive and patients with anemia should be treated. 
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11. Ragni MV et al. (1995)27 reported Randomized study of didanosine monotherapy and 
combination therapy with zidovudine in hemophilic and non hemophilic subjects with 
asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups and have 
stated that the correlation observed between CD4 and quantitative viral titer suggests that 
reduction in viral load is accompanied by an increase in CD4. Given the imprecision of CD4 as a 
surrogate marker for clinical HIV disease progression, and it is possible that viral load 
quantitation, either alone or together with CD4, may provide a more predictive marker of disease 
progression and antiviral response and also summarized that didanosine monotherapy and 
combination therapy are well tolerated in asymptomatic HIV infection and result in significant 
CD4 increases and viral load reduction. 
 
 
12. Raoul Moh et al. (1995)28 have studied the Haematological changes in adults 
receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte 
d’Ivoire and have concluded that cotrimoxazole and AZT are two important first-line HIV drugs 
with potential haematotoxic effects. Our data suggest that in patients receiving both drugs, severe 
neutropenia may be more frequent in sub-Saharan Africa than in industrialized countries. 
Administering both drugs to individuals similar to those who participated in our study requires 
close monitoring of the absolute neutrophil count and the discontinuation of cotrimoxazole in 
cases of severe neutropenia. 
 
 
13. Merigan TC et al. (1991)29 studied the Placebo-controlled trial to evaluate zidovudine 
in treatment of human immunodeficiency virus infection in asymptomatic patients with 
hemophilia.  
 
14. Robert E et al. (1988)30 investigated the anemia and erythropoiesis in patients with 
the acquired immune deficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine 
and have concluded that the anemia associated with zidovudine therapy is due to red cell 
hypoplasia or aplasia. 
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 3. AIM AND OBJECTIVE OF THE STUDY 
                                                     
                                           
 
RATIONALE OF THE STUDY 
 
             There are about 33 million people in the world suffering from AIDS (“a dying weigh of 
life) which foreshadows its explosion to various opportunistic diseases and has reached epidemic 
proportions globally with at least 2 million people dying each year. 
 
 
AIM AND OBJECTIVE 
 
              The present study was to evaluate the basic hematological parameters of the persons 
developing anemia due to zidovudine and to understand the effect of zidovudine on 
haematogenesis and to explore alternate possible medications. 
 The purpose of this study was to analyze the drug profile in related to laboratory test and 
clinical data to determine when starting ARV therapy, stopping or changing therapy because of 
either side-effect/toxicity or treatment failure. 
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4.  PLAN OF WORK 
 
 
 
 
 
                                                                Fig 5: Plan of work 
 
 
 
 
Selection of 
HIV positive 
patients 
confirmed by 
ELISA & 
western blot 
assay
Recording 
their history & 
details
Recording the 
Hematological 
&other 
parameters at 
the initiation of 
Antiretroviral 
therapy with 
Zidovudine
Hematological 
assessment after 3 
months of 
treatment due to 
complaints of 
various symptoms 
& treatment
Assessment of 
parameters 
after 2 & 6 
weeks of 
Changeover of 
Antiretroviral 
drug regimen
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5. METHODOLOGY 19, 21, 23 
 
PATIENTS AND METHODS 
  The study method used was cohort which used observational method with 
descriptive analysis. The subjects observed were hospitalized HIV/AIDS patients at Catherine 
Booth hospital, Nagercoil. All the patients under this study were receiving anti-retroviral therapy 
and were determined by enzyme linked immuno sorbent assay (ELISA) and were confirmed by 
Western blot assay. 
 
 The important Hemoglobin parameter was assessed by Sahli-Adams (tube) method. 
 
 
CRITERIA FOR INCLUSION: 
 Age  between  18-65 
 HIV positive 
 Zidovudine treatment 
 
 
CRITERIA FOR EXCLUSION: 
 Patients on other medications 
 Defaulters 
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CASE 1 
 
  
 
 
 
 
 
 
 
We report a 37 year old female diagnosed with HIV infection who was referred to 
hospital for initiation of Highly Active Anti-Retroviral Therapy (HAART).Baseline 
investigations revealed hemoglobin 12.8 g, WBC count 5400 cells/mm3 and a platelet count of 
132000 cells/mm3. Urine examination, renal parameters and liver functions were within normal 
limits. 
 
 She was started on ZLN therapy daily on 25.06.2013. After 3 weeks, blood picture was 
revealed hemoglobin 11.9 g, WBC count 5200 cells/mm3 and a platelet count of 189000 
cells/mm3. 
 
 After 3 months, she presented symptoms of tiredness, palpitation, swelling of both legs 
which she suffered for past 2 weeks. Analysis was made. Her blood pressure was found to be 
90/60 mm/Hg and the pulse rate was 120/min. Hemoglobin was 3.3, WBC count was 4700 
cells/mm3 and the platelet count was 192000 cells/mm3. 
 
 In urine, renal, liver parameters estimation, all was within normal levels except SGPT 
which showed 127 IU/L which was highly abnormal. Erythrocyte sedimentation rate was also 
high showing 40 mm/hr. 
 
            Patient name    :  PLHA-1 
  Age & Sex   : 37 & Female 
Blood Group : B positive 
 
 
                                                                                                                            METHODOLOGY 
 
Dept.of Pharmacy Practice, JKKN, Kumarapalayam Page 19 
 
 Hematological investigations confirmed the presence of macrocytic anemia .Treatment 
was given to treat anemia and antiviral therapy was changed to SLN. After 2 weeks and 6 weeks 
hematological changes were recorded. 
 
TREATMENT: 
 
                                                 Table 4: Treatment given in case 1 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 st day 
2 nd day 
3 rd day 
 
DRUG 
 
 
STRENGTH 
 
FREQUENCY 
 
ROUTE 
T.livogen  1 BD Oral 
T.rantac (150 mg) BD Oral 
T.mebex (100 mg) BD Oral 
Inj.lasix (20 mg) OD i.v 
T.liv 52  2 BD Oral 
T.limarin (140 mg) BD Oral 
Tranfusion 1 pint  i.v 
4 th day Inj.febrinil 1 amp  i.v (PRN) 
Tranfusion 1 pint  i.v 
 
5 th day 
Tranfusion 1 pint  i.v 
Inj.lasix 20 mg  i.v 
Inj.avil 1 amp  i.v 
 
 
Discharge   
Medicines 
× 5 days 
T.livogen  1 BD Oral 
T.rantac  1 BD Oral 
T.liv 52  2 BD Oral 
T.limarin 140 mg BD Oral 
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CASE 2 
 
 
      
 
 
 
Here we report a 49 year old male who was considered HIV positive before 5 months and 
was taking ZLN antiretroviral therapy for the past 2 months. At the start of the therapy             
(ie. On  01 .03.2013) his Hb was 11.8 g, WBC was 6000 cells/mm3, other parameters like total 
bilirubin, direct bilirubin, calcium, potassium, SGOT, SGPT were normal. Suddenly he 
complained that he suffered from breathlessness on exute, fatigue. 
Hematological and other parameters was assessed .Hb was 2.5 g, Liver function tests 
were normal ,white blood cells were within normal limits, renal parameters like total bilirubin, 
direct bilirubin, sodium ,potassium levels also represented normal values. 
 Anemia was confirmed and treatment was given and after 2 weeks all blood and other 
parameters was assessed. 
 
 
 
 
 
             Patient name :            PLHA-2 
Age & Sex : 49 & Male 
Blood Group : O positive 
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TREATMENT 
                                          Table 5: Treatment given in case 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 st day 
DRUG 
 
STRENGTH FREQUENCY ROUTE 
T.tenolam  1 -0-0 Oral 
T.nevirapine   1-0-1 Oral 
T.livogen   1 BD Oral 
Inj.lasix  (20 mg) OD i.v  
T.sepmax  2 BD Oral 
Syr. ambrodiol 10 ml TDS Oral 
 
 
2 nd day 
Inj.deriphylline 1 amp  i.v   
 Q 8 H 
Inj.lasix 20 mg  i.v stat 
Inj.avil 1 amp  i.v stat 
Transfusion 1 pint   
Ipravent 
nebulization 
  Q 6 H 
 
        3 rd day 
Tranfusion 1 pint   
Inj.lasix 20 mg  i.v 
Inj.avil 1 amp  i.v stat 
Inj.dexa 4 mg  i.v stat 
 
         4 th day 
Tranfusion 
Inj lasix 
1 pint 
20 mg 
  
i.v stat 
Inj avil 1 amp  i.v stat 
         
         5 th day 
T rantac 150 mg BD Oral 
Tranfusion 1 pint   
T infiniar  HS Oral 
Inj. oframax 1 gm BD i.v 
        
       6 th day 
Tranfusion 1 pint   
Inj.lasix 20 mg  i.v PRN 
Inj.avil 1 amp  i.m PRN 
       7 th day Tranfusion 1 pint   
Inj.lasix 20 mg  i.v PRN 
Inj avil 1 amp  i.v stat 
Ipravent 
nebulization 
 BD  
Inj.deriphylline 1 amp  i.v stat 
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CASE 3 
 
  
 
 
 
 
 
 
 
A 37 year old male who was confirmed HIV positive in the month of May was given 
ZLN therapy .After 3 months he was admitted as he was suffering from symptoms like difficulty 
in walking, irrelevant talk, fever since morning, cough. He had no complaints of vomiting, loose 
stools and dissuria. Examination findings reported a pulse rate of 120/min, blood pressure was 
100/50 mm/Hg and also he was reported to have spleenomegaly.  
 
Hemoglobin was 2.1 g and the WBC count was 2000 cells/mm3 (Neutrophils-67%, 
Lymphocytes-30%, Eosinophils-0.3%.Platelet count was 66,0000 cells/mm3.SGPT, SGOT, 
serum creatinine, serum amylase were within normal limits 40 IU/L, 46 IU/L, 1.3 mg%, 77 IU/L 
respectively. 
 
 The diagnosed value indicates clearly that the patient was suffering from anemia and also 
neutropenia which is characterized by decreased white blood cells. 
 
 Treatment was given based on his exhibited complications. 
 
 
 
 
 
             Patient name :  PLHA-3 
Age & Sex : 37 & Male 
Blood Group : O positive 
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TREATMENT 
                                               Table 6: Treatment given in case 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
       
 
 
 
 
 
        1 st day 
 
DRUG 
 
 
STRENGTH 
 
FREQUENCY 
 
ROUTE 
Inj.oframax 1 gm  i.v 
Q 8 H 
Inj.rantac 50 mg  BD i.v 
Inj.lasix  (20 mg)  i.v stat 
T.livogen  1 BD Oral 
Inj.febrinil 1 amp  i.v stat PRN 
Inj.emeset 4 mg  i.v PRN 
T.sepmax 1 HS  Oral 
T.dolo 650 mg  PRN 
T.antican-O 150 mg OD Oral 
Transfusion 20 pint   
T.SLN  1-0-1 Oral 
Inj.avil 1 amp  i.m stat 
 
 
2 nd day 
 3 rd day 
Transfusion 1 pint   
 
Inj.lasix 20 mg  i.v stat 
Inj.avil 1 amp  i.v stat 
Inj.oframax 1 gm  i.v 
Q 8 H 
T.sep max  1 HS  
Oral 
 
        4 th day 
Inj.oframax 1 gm  i.v 
Q 8 H 
T.sep max  1 HS Oral 
 
         5 th day 
Tranfusion 1 pint   
Inj avil 1 amp  i.v stat 
Inj.lasix 20 mg  i.v stat 
T.livogen  1 BD Oral 
         
         6 th day 
Transfusion 10 pints   
 
Inj.lasix 20 mg  i.v stat 
Inj.avil 1 amp  i.v stat 
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CASE 4 
 
 
 
 
 
 
 
 
 
We report a 35 year old patient of blood group O positive who was admitted in hospital 
due to various complaints like fever for 1 week, giddiness, fatigue and vomiting for a day who 
was on the treatment with anti-retroviral therapy for the past 3 months as she was confirmed with 
HIV with ELISA and western blot assay. 
 
Various blood parameters and other organ function tests were carried out and was found 
that the Hb was only 3.9 g % which reduced from 12.4 g at the time of initiation of Antiretroviral 
therapy. All other levels were within normal limits. 
 
 This indicated that Anemia was the keen cause for the symptoms and corresponding 
treatment was given. 
 
 
 
 
 
 
 
 
 
            Patient name  :  PLHA-4 
 Age & Sex   :   35 & Female 
Blood Group : O positive 
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TREATMENT 
                                        Table 7: Treatment given in case 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 st day 
 
 
DRUG 
 
 
STRENGTH 
 
FREQUENCY 
 
ROUTE 
Transfusion 1 pint   
Inj.lasix 20 mg  i.v stat 
Inj.avil 1 amp  i.v stat 
Inj.emeset 4 mg  TDS i.v 
T.sepmax  HS Oral 
C.becosules  1 OD i.v stat 
T.livogen  1 BD Oral 
T.tenolam  1 HS Oral 
T.efavirenz  1 HS Oral 
T.liv 52 600 mg 2 BD Oral 
T.limarin 140 mg BD Oral 
Transfusion 1 pint Over 5-6 hrs  
Inj.mol 1 amp  i.m stat 
T.alprax 0.5 mg  Stat 
 
2 nd day 
Transfusion 1 pint Over 6 hrs  
Inj.lasix 20 mg  i.v stat 
Inj.avil 1 amp  i.v stat 
 
 
3 rd day 
Tranfusion 1 pint   
Inj.lasix 20 mg  i.v 
Inj.avil 1 amp  i.v stat 
Inj.perinom   i.v stat 
T.perinom 10 mg TDS Oral 
 
 
Discharge      
medicines 
T.emeset 4 mg TDS× 3 days Oral 
T.sepmax  1 HS×5 days i.v stat 
T.liv 52  2 BD×5 days Oral 
T.livogen  1 BD×5 days Oral 
T.alprax 0.25 mg HS-OD×5 days Oral 
C.omez 20 mg BD ½  hr before 
meals 
Oral 
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CASE 5: 
  
 
  
 
 
 
 
Here we present a case study of a HIV patient associated with TB infection of age 43 
years old .He was considered HIV positive after the ELISA test and confirmation with western 
blot test in the month Jan 2013.He was prescribed with Anti-retroviral therapy. 
 In the month of April 2013, this patient had complaints of certain symptoms of fever for 
4 days, swelling of both legs, he had regular hiccups, reduced intake, ulcers in mouth, coughing 
up phlegm and blood, fatigue, chest pain for past 2 weeks. He was diagnosed and the 
examination findings showed that is blood pressure was 110/60 mm/Hg, pulse rate of 120/min, 
CD4 count was only 93 cells/mm
3. 
He was also evaluated for certain renal, liver parameters and the SGPT was 90 IU/L, 
SGOT-184 IU/L. Sodium, potassium levels, serum creatinine was within normal limits.ESR was 
found to be 116 and the WBC count was 2200 cells/mm3.Platelet count was 72000 
cells/mm3.RBC count was 5.8 g Sputum culture test was also performed which showed positive 
result indicating mycobacterium.  
Blood calcium level was 11.7 mg/dl. Microscopic examination in spleen and liver was 
done as a result coarse nodule is seen in spleen, minimal ascitis was observed. Uric acid crystals 
and few epithelial cells were also observed. 
             Patient name :  PLHA-5 
Age & Sex : 43 & Male 
Blood Group : B positive 
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 This analysis indicates that the patient is associated with Disseminated TB, 
Hepatospleenomegaly, Hypercalcemia due to TB, Anemia, Neutropenia, Thrombocytopenia. 
Fever evaluation confirmed the fever as Dengue.  
Treatment was given to improve the patient from the symptoms he was suffering. 
 
TREATMENT 
                                      Table 8: Treatment given in case 5 
 
1 st day 
 
 
DRUG 
 
 
STRENGTH 
 
FREQUENCY 
 
ROUTE 
T.largatil 25 mg BD Oral 
IVF.RL 2.0 RL stat i.v 
 T.livogen  1 BD Oral 
2 nd day IVF.RL 1.0 RL Over 6 hrs i.v 
 
3 rd day 
IVF.RL 1.0 RL  i.v 
DNS 1.0  i.v 
 
4 th day 
Inj .pantoprazole 40 mg  i.v 
T.aciloc RD  1-0-1 Oral 
T.largatil 25 mg BD Oral 
T.lasix 20 mg  Oral 
Transfusion 1 pint   
 
5 th day 
T.largatil 25 mg BD Oral 
Tranfusion 1 pint   
T.lasix 20 mg  Oral 
Inj. Avil 1 amp  i.v stat 
 
6 th day 
DNS 10 Over 6 hrs i.v 
Inj.oframax 1 gm BD i.v 
Inj.rantac 50 mg BD i.v 
Inj. Amikacin O 150 mg OD i.v 
T.Sepmax   Oral 
T.Alcin 500 mg OD Oral 
T.Liv 52  2 BD Oral 
T.Livopill B  1 BD Oral 
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T.Aciloc RD  1 BD Oral 
T.Ethambutol 800 mg OD Oral 
T.Microdox 100 mg BD Oral 
T.Perinom 10 mg BD Oral 
 Inj.Avil 1 ampoule  i.v stat 
Inj. Mol 1 ampoule  i.v stat 
7 th day Inj.Pantoprazole 40 mg BD i.v 
Transfusion 10 pints   
Inj.Avil 1 ampoule  i.v stat 
Inj. Lasix 20 mg  i.v stat 
T. Inderal 20 mg BD Oral 
T.Alprax 0.25-0-0.5 mg  Oral 
8 th day T.Dolo 650 mg  Stat 
T.perinom 10 mg TDS Stat 
 
9 th day 
T.largatil 25 mg TDS Oral 
Inj.Oframax   i.v 
Inj.Amikacin   i.v 
T.INH 150 mg OD Oral 
 
 
 
 
Discharge 
Medicines 
T.INH 300 mg OD Oral 
T.Ethambutol 800 mg OD Oral 
T.Levofloxacin 500 mg OD Oral 
T.aciloc RD  1-0-1 Oral 
T.Sepmax  1 HS Oral 
T.Antican O 150 mg OD Oral 
T.largatil 25 mg TDS Oral 
T.Inderal 20 mg BD Oral 
T.Alprax 0.25-0-0.5 mg  Oral 
T.Limarin 140 mg BD Oral 
T.B6 40 mg OD Oral 
T.Ativan 1 mg-HS OD Oral 
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CASE 6: 
 
 
 
 
 
 
 
 
 
We report a 57 year old female diagnosed with HIV infection who was referred to 
hospital for initiation of Highly Active Anti-Retroviral Therapy (HAART).Baseline 
investigations revealed hemoglobin 12.4 g, WBC count 6000 cells/mm3 and a platelet count of 
321000 cells/mm3. Urine examination, renal parameters and liver functions were within normal 
limits. 
 
 She was started on ZLN therapy daily on 13.10. 2013. After 2 weeks, blood picture was 
revealed hemoglobin 3.9 g, WBC count 5900 cells/mm3 and a platelet count of 320000 
cells/mm3 as she presented with symptoms of tiredness and swelling of both legs. 
 
 Analysis confirmed the presence of red cell aplasia as there was no abnormality in the 
white blood cell count .Treatment was given to treat aplasia. 
 
 
 
 
 
            Patient name :  PLHA-6 
Age & Sex  : 57 & Female 
Blood Group : B Negative 
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TREATMENT: 
 
                                              Table 9: Treatment given in case 6 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 st day 
2 nd day 
3 rd day 
 
DRUG 
 
 
STRENGTH 
 
FREQUENCY 
 
ROUTE 
T.livogen  1 BD Oral 
T.rantac (150 mg) BD Oral 
T.mebex (100 mg) BD Oral 
Inj.lasix (20 mg)  i.v 
Inj.avil 1 amp  i.v 
T.liv 52  2 BD Oral 
Tranfusion 1 pint   
 
4 th day 
Inj.febrinil 1 amp  i.v (PRN) 
Inj. Dolonex 1 amp  i.m  stat. 
T.deriphylline (150 mg) BD Oral 
Tranfusion 1 pint   
 
5 th day 
Tranfusion 1 pint   
Inj.lasix 20 mg  i.v 
Inj.avil 1 amp  i.v 
 
 
Discharge   
Medicines 
× 7 days 
T.livogen  1 BD Oral 
T.rantac  1 BD Oral 
T.deriphylline 150 mg BD Oral 
T.liv 52  2 BD Oral 
T.limarin 140 mg BD Oral 
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CASE 7 
 
 
 
 
 
 
A 48 year old male patient who was confirmed HIV positive in the month of July was 
given ZLN therapy .After 2 weeks he was admitted as he was suffering from symptoms like 
difficulty in walking, irrelevant talk, fever since morning and tiredness.  
 
He had no complaints of vomiting, loose stools and dissuria. Examination findings 
showed that his hemoglobin was 4.0 g and the WBC count was 2100 cells/mm3.Platelet count 
were 251000 cells/mm3. SGPT was 95 and SGOT was 65.All the other assessed parameters were 
within limits. 
 
 The diagnosed value indicates clearly that the patient was suffering from anemia and also 
neutropenia. 
 
 
 
 
 
 
 
             Patient name :  PLHA-7 
Age & Sex : 48 & Male 
Blood Group : B Positive 
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TREATMENT 
                                                Table 10: Treatment given in case 7 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
        1 st day 
Inj.oframax 1 gm  i.v 
Q 8 H 
Inj.rantac 50 mg  BD i.v 
Inj.lasix  (20 mg)  i.v stat 
Inj.febrinil 1 amp  i.v stat 
PRN 
Inj.emeset 4 mg  i.v PRN 
T.sepmax 1 HS  Oral 
T.dolo 650 mg  PRN 
T.antican-O 150 mg OD Oral 
Transfusion 2 pints   
T.SLN  1-0-1 Oral 
T.livogen  1 BD Oral 
Inj.avil 1 amp  i.m stat 
 
 
2 nd day 
 3 rd day 
Transfusion 1 pint   
 
Inj.lasix 20 mg  i.v stat 
Inj.avil 1 amp  i.v stat 
Inj.oframax 1 gm  i.v 
Q 8 H 
T.sep max  1 HS oral 
 
 
        4 th day 
Inj.oframax 1 gm  i.v 
Q 8 H 
T.sep max  1 HS Oral 
 
         5 th day 
Tranfusion 1 pint   
Inj avil 1 amp  i.v stat 
Inj.lasix 20 mg  i.v stat 
T.livogen  1 BD Oral 
         
         6 th day 
Transfusion 1 pint   
 
Inj.lasix 20 mg  i.v stat 
Inj.avil 1 amp  i.v stat 
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6. RESULTS AND DISCUSSION 
 
All the patients under this study had a history of Zidovudine Antiretroviral therapy 
treatment. The existence of anemia out of 7 cases studied was in all. Haemoglobin levels 
were much deviating from the normal limit in all patients after 2-3 weeks of Anti-retroviral 
therapy. Certain patients also showed abnormal liver enzyme levels, white blood cells, 
platelet count which was accompanied by anemia. 
 
CASE 1 
                                    Table 11: Hematological assessment in case 1 
Z-Zidovudine       L-Lamivudine        N-Nevirapine     S-Stavudine 
 
                           Fig 6: Hemoglobin changes in case 1 
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Hemoglobin changes in case 1
DATE Hb 
(g) 
WBC 
cells/mm3 
Platelets 
Cells/mm3 
SGPT 
( IU/L) 
HAART 
25 JUN 2013 12.8 5400 132000 45 ZLN 
18 JUL 2013 11.9 5200 189000 90 ZLN 
20 OCT 2013 3.3 4700 192000 127 ZLN 
05 NOV 2013 4.5 4700 191000 112 SLN 
18 DEC 2013 7.3 4800 190000 99 SLN 
A-At the 
initiation of 
therapy 
B-After 3 weeks 
of ZLN therapy 
C-After 3 months 
of ZLN therapy 
D-After 2 weeks 
of SLN therapy 
E-After 6 weeks 
of SLN therapy 
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                                            Fig 7: SGPT changes in case 1 
 
After 2 weeks of change of drug regimen from ZLN to SLN, Hb was increased from 
3.3 to 4.5 and SGPT was from 127 to 92 and after 6 weeks the Hb was 9.7 and SGPT was 
64.These changes in hematological parameters clearly indicates that the anemia caused was 
induced by Zidovudine. 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
A B C D E
SGPT changes in case 1 45 90 127 112 99
S
G
P
T
 (
 I
U
/L
)
SGPT changes in case 1
A-At the 
initiation of 
therapy 
B-After 3 weeks 
of ZLN therapy 
C-After 3 months 
of ZLN therapy 
D-After 2 weeks 
of SLN therapy 
E-After 6 weeks 
of SLN therapy 
RESULTS AND DISCUSSION 
 
Dept.of Pharmacy Practice, JKKN, Kumarapalayam Page 35 
 
 
 
CASE 2 
                                   Table 12: Hematological assessment in case 2 
Z-Zidovudine       L-Lamivudine        N-Nevirapine   T-Tenofovir 
 
                                      
  
 
 
                      Fig 8: Hemoglobin changes in case 2 
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SGPT 
(IU/L) 
 
SGOT 
(IU/L) 
  Total 
Bilirubin 
(mg/dl) 
Direct 
Bilirubin 
(mg/dl) 
 
Na 
(mEq/L) 
 
K 
(mEq/L) 
 
HAART 
1MAR 
2013 
 
11.8 
 
6000 
 
17 
 
22 
 
0.9 
 
0.5 
 
130 
 
4 
 
ZLN 
18 
MAY 
2013 
 
2.5 
 
5200 
 
17 
 
23 
 
0.9 
 
0.2 
 
140 
 
4.4 
 
ZLN 
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JUN 
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4.4 
 
TLN 
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4.3 
 
TLN 
A-At the 
initiation of 
therapy 
B-After 3 months 
of ZLN therapy 
C-After 2 weeks 
of SLN therapy 
D-After 6 weeks 
of SLN therapy 
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Out of all the assessed parameters ,only Hb drastically reduced from 11.8 to 2.5.After 
change from  ZLN to TLN there was a increase in Hb from 2.5 to 5.8 and this anemia was 
drug induced that was caused by Zidovudine. 
 
CASE 3 
                                Table 13: Hematological assessment in case 3 
 
 
 
 
 
 
 
Z-Zidovudine       L-Lamivudine        N-Nevirapine     S-Stavudine 
 
 
 
                                        Fig 9: Hemoglobin changes in case 3 
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DATE Hb 
(g) 
WBC 
cells/mm3 
SGPT 
( IU/L) 
SGOT 
( IU/L) 
HAART 
30 MAY 2013 10.7 5000 35 44 ZLN 
06 AUG 2013 2.1 2000 40 46 ZLN 
   21 AUG 2013 4.8 3200 39 46 SLN 
   15 SEP 2013 5.8 3450 41 46 SLN 
A-At the 
initiation of 
therapy 
B-After 3 months 
of ZLN therapy 
C-After 2 weeks 
of SLN therapy 
D-After 6 weeks 
of SLN therapy 
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                                    Fig 10: WBC count changes in case 3 
 
After a change from Zidovudine to Stavudine, the hemoglobin value increased from 
2.1 to 4.8 g %.Also there was an increase in white blood cells. This drastic reduction in 
hemoglobin value was due to Zidovudine induced anemia. 
 
 
 
CASE 4 
                                  Table 14: Haematological assessment in case 4 
 
 
 
 
 
 
 
Z-Zidovudine       L-Lamivudine        N-Nevirapine     S-Stavudine 
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DATE Hb 
(g) 
WBC 
cells/mm3 
Platelets 
Cells/mm3 
HAART 
14 AUG 2013 12.4 6000 312000 ZLN 
29 AUG 2013 3.9 5900 320000 ZLN 
13 SEP 2013 7.1 5900 192000 SLN 
05 OCT 2013 10.2 6000 191000 SLN 
A-At the 
initiation of 
therapy 
B-After 3 months 
of ZLN therapy 
C-After 2 weeks 
of SLN therapy 
D-After 6 weeks 
of SLN therapy 
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                                      Fig 11: Hemoglobin changes in case 4 
 
The change of ZLN therapy to SLN therapy brought up the drastic reduction of Hb from 3.9 
to 7.1 and further after six weeks to 10.2 g %. 
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CASE 5 
                                   Table 15: Haematological assessment in case 5 
Z-Zidovudine       L-Lamivudine        E-Efavirenz     S-Stavudine 
 
 
 
                                Fig 11: Hemoglobin changes in case 5 
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Date RBC 
(g) 
WBC 
(cells/
mm3) 
Platelet 
(cells/
mm3) 
CD4 
(cell
s/m
m3) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
Ca 
(mg/
dl) 
Na 
(mE
q/L) 
K 
(m
Eq/
L) 
HAART 
10 JAN 
2013 
11.5 5600 110000 234 32 26 9.1 136 4.5 ZLE 
02 APR 
2013 
5.8 2200 60000 93 184 90 11.7 132 4.2 ZLE 
21 APR 
2013 
7.2 2800 62000 132 76 73 10.9 132 4.3 SLE 
15 May 
2013 
7.6 2860 64000 163 70 67 10.1 130 3.8 SLE 
10 JUN 
2013 
8.5 3050 64000 171 70 68 10.1 131 4.1 SLE 
A-At the 
initiation of 
therapy 
B-After 3 months 
of ZLE therapy 
C-After 2 weeks 
of SLE therapy 
D-After 6 weeks 
of SLE therapy 
E- After 8 weeks 
of SLE therapy 
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                                  Fig 13: WBC count changes in case 5 
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                                   Fig 14: Platelet count changes in case 5 
 
 
 
 
                              Fig 15: SGOT & SGPT level changes in case 5 
              From the table, it is concluded that from a Hb value of 11.5 g, a prominent decrease 
of 5.8 was observed 2 weeks later after Anti retroviral therapy consisting of Zidovudine 
.After a changeover of Zidovudine to Stavudine there was a slight increase in Hb of upto 8.5 
gafter 8 weeks of treatment. Platelet count was also decreased from 110000 cells/mm3 to 
60000 which is much deviated from a normal value .Even after the changeover of drug, there 
was not a much increase in the platelet count. 
 This clearly indicates that the anemia caused was due to Zidovudine which was 
reversed after a change of drug from Zidovudine to Stavudine  
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CASE 6 
                                        Table 16: Hematological assessment in case 6 
 
 
 
 
 
 
 
Z-Zidovudine       L-Lamivudine        N-Nevirapine     S-Stavudine 
 
 
                                Fig 16: Hemoglobin changes in case 6 
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DATE Hb 
(g) 
WBC 
cells/mm3 
SGPT 
( IU/L) 
SGOT( 
IU/L) 
PLATELET 
( cells/mm3) 
HAART 
13 OCT  2013 10.9 3800 58 40 251000 ZLN 
28 OCT 2013 4.0 2100 95 65 250000 ZLN 
   12 NOV 2013 6.8 2200 87 59 249000 SLN 
   04 DEC 2013 7.9 3100 78 48 250000 SLN 
A-At the 
initiation of 
therapy 
B-After 3 months 
of ZLN therapy 
C-After 2 weeks 
of SLN therapy 
D-After 6 weeks 
of SLN therapy 
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                             Fig 17: WBC count changes in case 6 
 
After 2 weeks of change of drug regimen from ZLN to SLN, Hb was increased from 
3.9 to 7.1 and after 3 weeks the Hb was 10.2.These changes in hematological parameters 
clearly indicates that the anemia caused was induced by Zidovudine and was reversed after a 
changeover of treatment to Stavudine. 
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CASE 7 
                                  Table 17: Haematological assessment in case 7 
 
 
Z-Zidovudine       L-Lamivudine        N-Nevirapine     S-Stavudine 
 
 
 
 
 
 
                             Fig 18: Hemoglobin changes in case 7 
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WBC 
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SGOT 
( IU/L) 
SGPT 
(IU/L) 
HAART 
19 JUL 
2013 
11.1 4700 450000 42 64 ZLN 
21 SEP 
2013 
2.3 4500 460000 40 65 ZLN 
07 OCT 
2013 
6.2 4500 460000 41 60 SLN 
02 NOV 
2013 
8.0 4590 470000 40 62 SLN 
A-At the 
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After a change from Zidovudine to Stavudine, the hemoglobin value increased from 
4.0 to 6.8 and further to 7.9Also there was an increase in white blood cells from 2100 to 
3100. This drastic reduction in hemoglobin value was due to Zidovudine induced anemia. An 
increased level of SGPT and SGOT also showed a decrease. 
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                                               7. SUMMARY AND CONCLUSION 
 
• Seven different patients were studied who were confirmed HIV positive by ELISA and 
Western blot assay. 
•  The literature review showed that works have been performed in AIDS patients, 
especially in other parts of India, this study have attempted in Tamilnadu. 
•  All the patients under this study were on Anti-retroviral therapy. After 3 months of 
treatment, they presented with different symptoms like fatigue, swelling of legs etc…,  
• Various haematological analysis were performed and conditions like Anemia, 
Neutropenia, increase level of liver enzymes (SGOT & SGPT) and rarely 
thrombocytopenia was reported. 
• Based on their reports they were given different treatments including blood transfusion 
and antiretroviral therapy was changed.  
• After 2 weeks and 6 weeks, haematological parameters were analysed again and was 
found that there was improvement in haemoglobin and other parameters. 
• The observations and findings clearly indicated that the improvement in haematological 
parameters was due to changeover of drug Zidovudine to Stavudine and confirmed that 
Anemia which existed in all patients studied was induced by Zidovudine.  
• Out of 7 patients studied, Neutropenia, Thrombocytopenia, increased level of SGOT and 
SGPT was not found in all patients, but Anemia existed in all patients with a drastic 
reduction in Hemoglobin and was improved to an extent after changeover of 
antiretroviral drug regimen. 
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          A-At the initiation of Anti-retroviral therapy 
          B-After 3 months of treatment containing Zidovudine 
          C-After 2 weeks of treatment changeover to Stavudine 
          D- After 6 weeks of treatment changeover to Stavudine 
 
         Fig 18: Comparative Hemoglobin changes due to anemia in all 7 patients under study 
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CONCLUSION 
  
This study is concluded that Anemia is the most common hematologic abnormality 
associated with HIV infection. The incidence of anemia was found to be strongly associated with 
progression of HIV disease. People with anemia often suffer decreased quality of life as well as 
potential increased chance of mortality. While anemia may manifest as a mere laboratory 
abnormality in some individuals, others may experience typical symptoms (eg, fatigue, dyspnea, 
reduced exercise tolerance, diminished functional capacity) directly related to a reduction in 
hemoglobin concentration. It is important to remember that despite the potential side effects of 
these drugs, they may be essential for treatment of HIV infection or its complications, so they 
should not necessarily be avoided. Rather, people should be aware that side effects are a 
possibility and make efforts to identify and treat them. 
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